中国维生素月报

On 28 Oct., 2025, ZMC announced plans to invest USD237.77 million (RMB1,685 million) in the ZMC Changbei Bio construction project.

On 30 Oct., 2025, Tianxin Pharma released its financial report for Q3 2025.

In mid-November 2025, Hangzhou Minsheng Healthcare Co., Ltd. issued a statement addressing recent gross margin fluctuations.

Project Progress of Multiple Companies

• EI report for BASF Vitamin's expansion and renovation project was accepted.
• EI report for L&P Food's 500 t/a nutrition enhancer folic acid project was approved.
• EI report for the Xinweirong Chemical's vitamin derivatives series products project (Phase II) was publicised.
• EI report for the 1,400 t/a bio-fermented series products project of Keming Biomedical was announced to be approved.
• EI report for Huachen Pharmaceutical's vitamin B5 production equipment upgrading project was accepted.

The USD/RMB exchange rate in this Report is USD1.00=CNY7.0867 on 3 Nov. 2025, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.